.svg)
A closer look at a lesser-known Lachnospiraceae member
This test analyzes DNA from a small stool sample to quantify the relative abundance of Faecalicatena contorta and place it in the broader context of your gut microbiome. Modern sequencing approaches—such as 16S rRNA profiling or metagenomic analysis—detect and estimate microbial composition with high resolution, enabling comparison to reference populations and trend-tracking over time. Results reflect your current ecosystem balance rather than a fixed trait, since the microbiome changes with diet, stress, medications, and illness.
Why focus on Faecalicatena contorta? It is a Gram-positive, anaerobic member of the family Lachnospiraceae that has been isolated from human stool and clinical specimens. Some strains participate in carbohydrate fermentation and may contribute to short-chain fatty acid pools, while emerging work suggests potential roles in bile-acid transformation pathways—mechanisms tied to barrier integrity, inflammation, and metabolic signaling. Science here is evolving, so interpretation is contextual and trend-based.
Why a single Lachnospiraceae species can be worth measuring
Connecting the biology to daily life starts with pattern-spotting. Testing can identify when Faecalicatena contorta is unusually low or high relative to your peers and your own baseline. That matters because shifts in specific Lachnospiraceae, alongside overall diversity, often parallel changes in digestion, gas and bloating patterns, stool form, skin flares, or immune reactivity. Results can also clarify the “after-effects” of antibiotics, restrictive diets, or chronic stress, and they’re particularly useful after major lifestyle changes or during persistent GI symptoms.
Zooming out, your gut community influences glucose regulation, lipid and bile metabolism, mucosal inflammation, and even mood through the gut–brain axis. Repeating microbiome testing over time helps you see whether fiber upgrades, targeted probiotics, or stress-reduction practices are nudging your ecosystem toward greater diversity and stability. The goal isn’t a perfect number. It’s understanding your signature and how it responds, then pairing that knowledge with other labs—like inflammatory or metabolic panels—for prevention and long-term wellness planning.
Making sense of the number on the page
Your report typically shows Faecalicatena contorta as a percentage of total bacterial reads, often alongside a diversity score and the relative abundance of other key taxa. Many labs also benchmark your values to reference cohorts so you can see “lower than typical,” “within typical,” or “higher than typical.” In general, more diverse microbiomes—often richer in beneficial genera such as Bifidobacterium and Faecalibacterium—are linked with resilient gut function, while marked overrepresentation of a few species may suggest imbalance.
Balanced or “optimal for you” results often align with efficient fermentation of fibers, healthy short-chain fatty acid production, low inflammatory signaling, and a stable gut barrier. Optimal ranges vary widely across individuals, influenced by genetics, geography, and diet, so trends over time are more informative than a single snapshot.
Imbalanced or “dysbiotic” patterns might include reduced diversity, expansion of inflammation-associated species, or loss of helpful fermenters. For Faecalicatena contorta specifically, context matters: certain strains have been linked with acetate production and putative bile-acid–modifying genes, so very low or very high levels may flag areas to explore with nutrition, prebiotic substrates, or medical evaluation if symptoms persist. These are functional clues, not diagnoses, and they’re best interpreted with your clinician.
The honest read on what this test offers
Big picture, a Faecalicatena contorta result is most powerful when viewed alongside other biomarkers and your lived experience. Pairing microbiome data with inflammation markers, metabolic panels, and symptom timelines turns numbers into insight—helping you personalize strategies for smoother digestion, steadier energy, and long-term health optimization.
FAQs
The Faecalicatena contorta test analyzes the genetic material (DNA/RNA) from bacteria, fungi, and other microorganisms in a stool sample to identify which species are present, their relative abundance, and the community’s functional potential (for example metabolic pathways or resistance genes).
Results describe the microbial composition and balance of the gut microbiome and suggest functional capabilities but do not, by themselves, diagnose a disease—clinical correlation and further testing are required to determine disease presence.
A faecalicatena contorta sample is collected at home using the sterile collection kit provided — typically a small swab or a tiny vial supplied in the kit. You collect a small amount of stool following the kit’s step‑by‑step instructions, place the swab or sample into the provided container, and securely seal it.
Maintain good hygiene (wash hands before and after), avoid contaminating the sample with urine or water, clearly label the container with the required patient information, and follow the kit instructions exactly — these steps are essential to ensure accurate sequencing results.
Faecalicatena contorta test results can provide clues about how that species may be influencing your gut ecosystem — for example, they can suggest effects on digestion (via interactions with other microbes and fermentation of dietary components), local inflammation, nutrient absorption, metabolic activity (short‑chain fatty acid and other metabolite production), and potential pathways of gut–brain communication that may influence mood or nervous‑system signalling.
These microbiome patterns can correlate with certain physiological states or risks but do not by themselves diagnose specific diseases; results are one piece of the puzzle and are best interpreted alongside symptoms, clinical tests, and medical history with a healthcare professional.
Next‑generation sequencing provides high‑resolution microbial data and can sensitively detect and quantify Faecalicatena contorta DNA in a stool sample, but interpretation of Faecalicatena contorta test results is probabilistic: reported presence or relative abundance indicates likelihoods and associations rather than definitive proof of disease or function, and results depend on laboratory methods, sequencing depth and bioinformatic reference sets.
Test results represent a single snapshot in time and can change with recent diet, stress, bowel transit and especially recent antibiotic use, so findings may vary between samples and are best interpreted alongside clinical context or repeat sampling when needed.
Many people test their faecalicatena contorta once per year to establish a baseline, or every 3–6 months if they are actively adjusting diet, probiotics, medications, or other interventions to monitor response.
It’s more valuable to compare trends over time than to rely on a one‑off reading—serial tests show direction and magnitude of change and reduce the impact of short‑term variability, so use consistent sampling methods and the same lab when possible to make comparisons meaningful.
Yes — microbial populations, including those of faecalicatena contorta, can shift quickly: changes in diet, medication, travel, sleep, or other lifestyle factors can alter relative abundances within days, but broader, reproducible community patterns and a stable baseline typically emerge over weeks to months.
For meaningful comparisons, keep diet and lifestyle as consistent as possible and wait several weeks (often a few weeks to a few months depending on the change) before retesting so observed differences reflect durable shifts rather than short-term fluctuations.
References
- Sakamoto, M., Iino, T., & Ohkuma, M. (2017). Faecalimonas umbilicata gen. nov., sp. nov., isolated from human faeces, and reclassification of Eubacterium contortum, Eubacterium fissicatena and Clostridium oroticum as Faecalicatena contorta gen. nov., comb. nov., Faecalicatena fissicatena comb. nov. and Faecalicatena orotica comb. nov. International Journal of Systematic and Evolutionary Microbiology, 67(5), 1219-1227. https://doi.org/10.1099/ijsem.0.001790
- Vacca, M., Celano, G., Calabrese, F. M., Portincasa, P., Gobbetti, M., & De Angelis, M. (2020). The controversial role of human gut Lachnospiraceae. Microorganisms, 8(4), 573. https://doi.org/10.3390/microorganisms8040573
- Parada Venegas, D., De la Fuente, M. K., Landskron, G., González, M. J., Quera, R., Dijkstra, G., Harmsen, H. J. M., Faber, K. N., & Hermoso, M. A. (2019). Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Frontiers in Immunology, 10, 277. https://doi.org/10.3389/fimmu.2019.00277
- Laudadio, I., Fulci, V., Palone, F., Stronati, L., Cucchiara, S., & Carissimi, C. (2018). Quantitative assessment of shotgun metagenomics and 16S rDNA amplicon sequencing in the study of human gut microbiome. OMICS, 22(4), 248-254. https://doi.org/10.1089/omi.2018.0013
- Porcari, S., Mullish, B. H., Asnicar, F., Ng, S. C., Zhao, L., Hansen, R., O'Toole, P. W., Raes, J., Hold, G., Putignani, L., Hvas, C. L., Nieuwdorp, M., Sokol, H., Ianiro, G., & Cammarota, G. (2025). International consensus statement on microbiome testing in clinical practice. The Lancet Gastroenterology & Hepatology, 10(2), 154-167. https://doi.org/10.1016/S2468-1253(24)00311-X
.avif)
.svg)
.svg)
